A retrospective analysis on optimal medical therapy for patients with symptomatic lower extremity peripheral artery disease: a French observational study.
Humans
Peripheral Arterial Disease
/ drug therapy
Retrospective Studies
Male
Female
Aged
Lower Extremity
/ blood supply
France
/ epidemiology
Middle Aged
Treatment Outcome
Platelet Aggregation Inhibitors
/ therapeutic use
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
Cholesterol, LDL
/ blood
Angiotensin-Converting Enzyme Inhibitors
/ therapeutic use
Dyslipidemias
/ drug therapy
Risk Factors
Drug Therapy, Combination
Angiotensin Receptor Antagonists
/ therapeutic use
Prevalence
Aged, 80 and over
Time Factors
Lipid objectives
Peripheral artery disease
Treatment
Triglycerides
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
01 Nov 2024
01 Nov 2024
Historique:
received:
17
11
2023
accepted:
23
10
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
Patients with symptomatic lower extremity artery disease (LEAD) should have an optimal management in terms of lipid goal [i.e. controlled LDL-cholesterol (LDLc)] and medical treatment (triple therapy with an antiplatelet agent, a statin and an angiotensin-converting enzyme inhibitor or a angiotensin-receptor antagonist). Prevalence of LEAD patients with a LDLc < 0.55 g/l is unknown. Aims of this study were to: (i) describe the prevalence of patients with a LDLc < 0.55 g/l, (ii) describe the prevalence of patients with an optimal medical treatment; (iii) compare this management between patients with a vascular surgery history and those without a vascular surgery history; and (iv) evaluate the number of patients eligible for new lipid-lowering therapies according to FOURIER and REDUCE-IT criteria. In this single-center retrospective study, prevalence is expressed as numbers and percentages. Comparison of the number of well managed patients between LEAD patients with a vascular surgery history and those without was performed. Number of patients who would be eligible for FOURIER and REDUCE-IT studies were calculated. Among the LEAD patients included in the analysis (n = 225), only 12.4% (n = 28) had a LDLc < 0.55 g/L. The prevalence of patients who received the optimal medical treatment was 50.7% (n = 114). There was no statistical difference in the prevalence of patients with and without vascular surgery history achieving the LDLc goal (n = 9 (10.6%) vs. n = 19 (13.6%); p = not significant). Ninety-three patients (46.0%) would be eligible for EVOLOCUMAB treatment according to the Fourier study design whereas 17 patients (8.4%) would be eligible for treatment with ICOSAPENT ETHYL according to the REDUCE-IT study design. A majority of LEAD patients did not reach the LDLc goals. LEAD patients with a vascular surgery history did not experience a better management whereas they had a more consistent follow-up.
Identifiants
pubmed: 39482624
doi: 10.1186/s12872-024-04289-w
pii: 10.1186/s12872-024-04289-w
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Cholesterol, LDL
0
Angiotensin-Converting Enzyme Inhibitors
0
Angiotensin Receptor Antagonists
0
Types de publication
Journal Article
Observational Study
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
611Informations de copyright
© 2024. The Author(s).
Références
Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. <ArticleTitle Language=“En”>Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019;7:e1020–30.
doi: 10.1016/S2214-109X(19)30255-4
pubmed: 31303293
Aday AW, Matsushita K. Epidemiology of Peripheral Artery Disease and Polyvascular Disease. Circ Res. 2021;128:1818–32.
doi: 10.1161/CIRCRESAHA.121.318535
pubmed: 34110907
pmcid: 8202714
Bauersachs R, Zeymer U, Brière J-B, Marre C, Bowrin K, Huelsebeck M. Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review. Cardiovasc Ther. 2019;2019:e8295054.
doi: 10.1155/2019/8295054
Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a Period of 10 Years in Patients with Peripheral Arterial Disease. N Engl J Med. 1992;326:381–6.
doi: 10.1056/NEJM199202063260605
pubmed: 1729621
Mahé G, Boge G, Bura-Rivière A, Chakfé N, Constans J, Goueffic Y, et al. Disparities Between International Guidelines (AHA/ESC/ESVS/ESVM/SVS) Concerning Lower Extremity Arterial Disease: Consensus of the French Society of Vascular Medicine (SFMV) and the French Society for Vascular and Endovascular Surgery (SCVE). Ann Vasc Surg. 2021;72:1–56.
doi: 10.1016/j.avsg.2020.11.011
pubmed: 33359707
Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas J-L, et al. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis. JAMA. 2006;295:180–9.
doi: 10.1001/jama.295.2.180
pubmed: 16403930
Aboyans V, Ricco J-B, Bartelink M-LEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763–816.
doi: 10.1093/eurheartj/ehx095
pubmed: 28886620
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376:1713–22.
doi: 10.1056/NEJMoa1615664
pubmed: 28304224
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11–22.
doi: 10.1056/NEJMoa1812792
pubmed: 30415628
Abraham P, Picquet J, Vielle B, Sigaudo-Roussel D, Paisant-Thouveny F, Enon B, et al. Transcutaneous oxygen pressure measurements on the buttocks during exercise to detect proximal arterial ischemia: comparison with arteriography. Circulation. 2003;107:1896–900.
doi: 10.1161/01.CIR.0000060500.60646.E0
pubmed: 12668524
Koch C, Chauve E, Chaudru S, Le Faucheur A, Jaquinandi V, Mahé G. Exercise transcutaneous oxygen pressure measurement has good sensitivity and specificity to detect lower extremity arterial stenosis assessed by computed tomography angiography. Med (Baltim). 2016;95:e4522.
doi: 10.1097/MD.0000000000004522
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA et al. /ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–143.
Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation. 2012;126:2890–909.
doi: 10.1161/CIR.0b013e318276fbcb
pubmed: 23159553
Chaudru S, de Müllenheim P-Y, Le Faucheur A, Kaladji A, Jaquinandi V, Mahé G. Training to Perform Ankle-Brachial Index: Systematic Review and Perspectives to Improve Teaching and Learning. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2016;51:240–7.
doi: 10.1016/j.ejvs.2015.09.005
Stivalet O, Paisant A, Belabbas D, Omarjee L, Le Faucheur A, Landreau P, et al. Exercise testing criteria to diagnose lower extremity peripheral artery disease assessed by computed-tomography angiography. PLoS ONE. 2019;14:e0219082.
doi: 10.1371/journal.pone.0219082
pubmed: 31247050
pmcid: 6597112
Poulin A, Guilcher A, Omarjee L, Jaquinandi V, Gandon Y, Mahe G, et al. Validation of a software to perform exercise oximetry to diagnose arterial stenosis of the lower limbs. Atherosclerosis. 2018;278:325–7.
doi: 10.1016/j.atherosclerosis.2018.08.025
pubmed: 30177345
Stivalet O, Laneelle D, Omarjee L, Mahe G. Post-exercise criteria to diagnose lower extremity peripheral artery disease: Which one should I use in my practice? Vasc Med Lond Engl. 2019;24:76–7.
doi: 10.1177/1358863X18811932
Mahé G, Jaquinandi V. [Diagnosis of lower limb peripheral artery disease]. Presse Medicale Paris Fr 1983. 2018;47:47–55.
Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137:338–50.
doi: 10.1161/CIRCULATIONAHA.117.032235
pubmed: 29133605
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Tardif J-C, et al. Abstract 10627: Benefits of Icosapent Ethyl in Patients with Prior Peripheral Artery Disease: REDUCE-IT PAD. Circulation. 2021;144 Suppl1:A10627–10627.
McDermott MM, Mandapat AL, Moates A, Albay M, Chiou E, Celic L, et al. Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. Arch Intern Med. 2003;163:2157–62.
doi: 10.1001/archinte.163.18.2157
pubmed: 14557213
Sunderland M, De Jong M, Bates D. Vascular protection in patients with diabetes admitted for vascular surgery in a canadian tertiary care hospital: pilot study. Can J Hosp Pharm. 2013;66:227–32.
pubmed: 23950606
pmcid: 3743854
Dopheide JF, Papac L, Schindewolf M, Baumgartner I, Drexel H. Poor attainment of lipid targets in patients with symptomatic peripheral artery disease. J Clin Lipidol. 2018;12:711–7.
doi: 10.1016/j.jacl.2018.02.013
pubmed: 29574071
Kotseva K, Wood D, De Bacquer D, De Backer G, Rydén L, Jennings C, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23:636–48.
doi: 10.1177/2047487315569401
pubmed: 25687109
Randomized trial of the effects of cholesterol-lowering. with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45:645–e6541.
doi: 10.1016/j.jvs.2006.12.054
Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Goto S, et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014;35:2864–72.
doi: 10.1093/eurheartj/ehu080
pubmed: 24585266
pmcid: 4216432
Herrett E, Williamson E, Brack K, Beaumont D, Perkins A, Thayne A, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021;372:n135.
doi: 10.1136/bmj.n135
pubmed: 33627334
pmcid: 7903384
Bytyçi I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43:3213–23.
doi: 10.1093/eurheartj/ehac015
pubmed: 35169843
pmcid: 9757867
Charasson M, Mahé G, Le Brun C, Jaquinandi V, Rossignol E, Le Faucheur A, et al. Atherosclerosis knowledge - diagnosis and management in primary care. VASA Z Gefasskrankheiten. 2018;47:465–70.
doi: 10.1024/0301-1526/a000727
Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–72.
doi: 10.1093/eurheartj/ehx144
pubmed: 28444290
pmcid: 5837225
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379:2097–107.
doi: 10.1056/NEJMoa1801174
pubmed: 30403574
Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2531–40.
doi: 10.1016/j.jacc.2014.03.018
pubmed: 24691094
Wang D, Liu B, Tao W, Hao Z, Liu M. Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev 2015;2015(10):CD009580. https://doi.org/10.1002/14651858.CD009580.pub2
Das Pradhan A, Glynn RJ, Fruchart J-C, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med. 2022;387:1923–34.
doi: 10.1056/NEJMoa2210645
pubmed: 36342113
Thiney M, Della Schiava N, Ecochard R, Feugier P, Lermusiaux P, Millon A, et al. Effects on Mortality and Cardiovascular Events of Adherence to Guideline-Recommended Therapy 4 Years after Lower Extremity Arterial Revascularization. Ann Vasc Surg. 2018;52:138–46.
doi: 10.1016/j.avsg.2018.03.021
pubmed: 29777848
Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation. 2011;124:17–23.
doi: 10.1161/CIRCULATIONAHA.110.003954
pubmed: 21690489
pmcid: 3139992
Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382:1507–19.
doi: 10.1056/NEJMoa1912387
pubmed: 32187462
Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med 2022;387(11):967–77.
doi: 10.1056/NEJMoa2208275
pubmed: 36477042